SOURCE: Spencer Pharmaceutical, Inc.

March 24, 2011 11:29 ET

Spencer Pharmaceutical Inc. Announces Publication in Major Scientific Journal of a Breakthrough Technology in Type 2 Diabetes

BOSTON, MA--(Marketwire - March 24, 2011) - (PINKSHEETS: SPPH) Spencer Pharmaceutical Inc. announced that the recently concluded agreement with Polyvalor, L.P. ( to license the inventions and future research results on type 2 Diabetes derived from the team headed by Professor Michael Buschmann at École Polytechnique de Montréal was published in one of the eminent scientific journals, Gene Therapy. This journal is one of the prestigious Nature series journals and is considered to be among the top scientific journals in the world. 

The abstract of the publication and the possibility to order the full paper can be found at the present link ( 

Using a well recognized animal model, intraperitoneal glucose tolerance tests revealed an efficacious decrease of blood glucose compared with controls for up to 24 days after a treatment with proprietary-patented nanocomplexes, where injections of this formulation allowed near-normalization of blood glucose level.

"This peer-reviewed publication is a major breakthrough in type 2 Diabetes research," said Dr. Max Arella, CEO of Spencer Pharmaceutical Inc. "The recognition of the scientific community through this peer-reviewed publication, renowned for the quality of its content, is a further confirmation of the quality of the work performed by Professor Michael Buschmann," added Dr. Arella. "The recognition of the scientific community of one of our projects in the pipeline is a solid confirmation of the seriousness of our science."

Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information

About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release. Although there is an offer currently coming from a third party, the Company can provide no assurances that the offer will be made, the timelines achieved, or the minimum offer will be realized.

Contact Information

  • Contact:

    Ian Morrice
    Executive Vice President and Director
    Spencer Pharmaceutical Inc.
    1+(617) 973-5017